TLR2/6 and TLR4-activated macrophages contribute to islet inflammation and impair beta cell insulin gene expression via IL-1 and IL-6

Diabetologia

Volumn 57, Issue 8, 2014, Pages 1645-1654

  Nackiewicz, Dominika ^a   Dan, Meixia ^a   He, Wei ^b   Kim, Rosa ^a   Salmi, Anisa ^a   Rütti, Sabine ^c   Westwell Roper, Clara ^a   Cunningham, Amanda ^a   Speck, Madeleine ^a   Schuster Klein, Carole ^d   Guardiola, Beatrice ^d   Maedler, Kathrin ^b   Ehses, Jan A ^a,e  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BREMEN   (Germany)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d ADIR   (France)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Beta cell; Diabetes; Inflammation; Pancreatic islet; Toll like receptor 2; Toll like receptor 4

Indexed keywords

INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; INTERLEUKIN 1; TOLL LIKE RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CELL SELECTION; CONTROLLED STUDY; CYTOKINE RELEASE; FLOW CYTOMETRY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; INS1 GENE; INS2 GENE; INSULIN RELEASE; MACROPHAGE ACTIVATION; MACROPHAGE FUNCTION; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET DISEASE; PANCREAS ISLET INFLAMMATION; PDX1 GENE; PRIORITY JOURNAL; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; MACROPHAGE; METABOLISM; PANCREAS ISLET; RAT;

ANIMALS; GENE EXPRESSION REGULATION; HUMANS; INSULIN; INSULIN-SECRETING CELLS; INTERLEUKIN-1; INTERLEUKIN-6; ISLETS OF LANGERHANS; MACROPHAGES; MICE, KNOCKOUT; RATS; TOLL-LIKE RECEPTORS;

EID: 84904743714     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3249-1     Document Type: Article

References (50)

1. Wellen KE, Hotamisligil GS (2005) Inflammation, stress, and diabetes. J Clin Invest 115:1111-1119 (Pubitemid 40629025)
2. Pickup JC, Crook MA (1998) Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41:1241-1248 (Pubitemid 28449093)
3. Donath MY, Shoelson SE (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11:98-107
4. Ehses JA, Perren A, Eppler E et al (2007) Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 56:2356-2370 (Pubitemid 47358243)
5. Richardson SJ, Willcox A, Bone AJ, Foulis AK, Morgan NG (2009) Islet-associated macrophages in type 2 diabetes. Diabetologia 52:1686-1688
6. Ehses JA, Lacraz G, Giroix MH et al (2009) IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci U S A 106:13998-14003
7. Jourdan T, Godlewski G, Cinar R et al (2013) Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat Med 19:1132-1140
8. Eguchi K, Manabe I, Oishi-Tanaka Y et al (2012) Saturated fatty acid and TLR signaling link beta cell dysfunction and islet inflammation. Cell Metab 15:518-533
9. Homo-Delarche F, Calderari S, Irminger JC et al (2006) Islet inflammation and fibrosis in a spontaneous model of type 2 diabetes, the GK rat. Diabetes 55:1625-1633 (Pubitemid 44324114)
10. Ehses JA, Meier DT, Wueest S et al (2010) Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet. Diabetologia 53:1795-1806
11. Dasu MR, Devaraj S, Park S, Jialal I (2010) Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care 33:861-868
12. Westwell-Roper C, Nackiewicz D, Dan M, Ehses JA (2014) Toll-like receptors and NLRP3 as central regulators of pancreatic islet inflammation in type 2 diabetes. Immunol Cell Biol 92:314-323
13. Creely SJ, McTernan PG, Kusminski CM et al (2007) Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 292:E740-E747 (Pubitemid 46411051)
14. Liang H, Hussey SE, Sanchez-Avila A, Tantiwong P, Musi N (2013) Effect of lipopolysaccharide on inflammation and insulin action in human muscle. PLoS One 8:e63983
15. Brun P, Castagliuolo I, Di Leo V et al (2007) Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 292:G518-G525
16. Cucak H, Grunnet LG, Rosendahl A (2014) Accumulation of M1-like macrophages in type 2 diabetic islets is followed by a systemic shift in macrophage polarization. J Leukoc Biol 95:149-160
17. Cani PD, Amar J, Iglesias MA et al (2007) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56:1761-1772 (Pubitemid 47025442)
18. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS (2006) TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116:3015-3025 (Pubitemid 44684486)
19. Tsukumo DM, Carvalho-Filho MA, Carvalheira JB et al (2007) Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 56:1986-1998 (Pubitemid 47195825)
20. Kuo LH, Tsai PJ, Jiang MJ et al (2011) Toll-like receptor 2 deficiency improves insulin sensitivity and hepatic insulin signalling in the mouse. Diabetologia 54:168-179
21. Himes RW, Smith CW(2010) Tlr2 is critical for diet-induced metabolic syndrome in a murine model. FASEB J 24:731-739
22. Poggi M, Bastelica D, Gual P et al (2007) C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance inwhite adipose tissue in response to a high-fat diet. Diabetologia 50:1267-1276 (Pubitemid 46701560)
23. Kim F, Pham M, Luttrell I et al (2007) Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ Res 100:1589-1596 (Pubitemid 46897262)
24. Vives-Pi M, Somoza N, Fernandez-Alvarez J et al (2003) Evidence of expression of endotoxin receptors CD14, toll-like receptors TLR4 and TLR2 and associated molecule MD-2 and of sensitivity to endotoxin (LPS) in islet beta cells. Clin Exp Immunol 133:208-218 (Pubitemid 36918595)
25. Wen L, Peng J, Li Z, Wong FS (2004) The effect of innate immunity on autoimmune diabetes and the expression of Toll-like receptors on pancreatic islets. J Immunol 172:3173-3180 (Pubitemid 38263708)
26. Boni-Schnetzler M, Boller S, Debray S et al (2009) Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 150:5218-5229
27. Amyot J, Semache M, Ferdaoussi M, Fontes G, Poitout V (2012) Lipopolysaccharides impair insulin gene expression in isolated islets of Langerhans via Toll-like receptor-4 and NF-kappaB signalling. PLoS One 7:e36200
28. Gibson DL, Montero M, Ropeleski MJ et al (2010) Interleukin-11 reduces TLR4-induced colitis in TLR2-deficient mice and restores intestinal STAT3 signaling. Gastroenterology 139:1277-1288
29. Ii M, Matsunaga N, Hazeki K et al (2006) A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-chloro-4-fluorophenyl) sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling. Mol Pharmacol 69:1288-1295
30. Matsunaga N, Tsuchimori N, Matsumoto T, Ii M (2011) TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules. Mol Pharmacol 79:34-41
31. Takashima K, Matsunaga N, Yoshimatsu M et al (2009) Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model. Br J Pharmacol 157:1250-1262
32. Westwell-Roper C, Dai DL, Soukhatcheva G et al (2011) IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction. J Immunol 187:2755-2765
33. Ribaux P, Ehses JA, Lin-Marq N et al (2007) Induction of CXCL1 by extracellular matrix and autocrine enhancement by IL-1 in rat pancreatic β-cells. Endocrinology 148:5582-5590 (Pubitemid 350012633)
34. Westwell-Roper CY, Ehses JA, Verchere CB (2014) Resident macrophages mediate islet amyloid polypeptide-induced islet IL-1beta production and beta cell dysfunction. Diabetes 63:1698-1711
35. Ellingsgaard H, Ehses JA, Hammar EB et al (2008) Interleukin-6 regulates pancreatic alpha-cell mass expansion. Proc Natl Acad Sci U S A 105:13163-13168
36. Calderon B, Suri A, Miller MJ, Unanue ER (2008) Dendritic cells in islets of Langerhans constitutively present beta cell-derived peptides bound to their class II MHC molecules. Proc Natl Acad Sci U S A 105:6121-6126 (Pubitemid 351758409)
37. Yin N, Xu J, Ginhoux F et al (2012) Functional specialization of islet dendritic cell subsets. J Immunol 188:4921-4930
38. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25:402-408 (Pubitemid 34164012)
39. Igoillo-Esteve M, Marselli L, Cunha DA et al (2010) Palmitate induces a pro-inflammatory response in human pancreatic islets that mimics CCL2 expression by beta cells in type 2 diabetes. Diabetologia 53:1395-1405
40. Wadt KA, Larsen CM, Andersen HU, Nielsen K, Karlsen AE, Mandrup-Poulsen T (1998) Ciliary neurotrophic factor potentiates the beta-cell inhibitory effect of IL-1beta in rat pancreatic islets associated with increased nitric oxide synthesis and increased expression of inducible nitric oxide synthase. Diabetes 47:1602-1608 (Pubitemid 28445348)
41. Novotny GW, Lundh M, Backe MB et al (2012) Transcriptional and translational regulation of cytokine signaling in inflammatory beta-cell dysfunction and apoptosis. Arch Biochem Biophys 528:171-184
42. Larsen CM, Faulenbach M, Vaag A et al (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517-1526 (Pubitemid 46588416)
43. Rissanen A, Howard CP, Botha J, Thuren T, for the Global I (2012) Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. Diabetes Obes Metab 14:1088-1096
44. Sloan-Lancaster J, Abu-Raddad E, Polzer J et al (2013) Double-blind, randomized study evaluating the glycemic and antiinflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes. Diabetes Care 36:2239-2246
45. Cavelti-Weder C, Babians-Brunner A, Keller C et al (2012) Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 35:1654-1662
46. van Asseldonk EJ, Stienstra R, Koenen TB et al (2010) The effect of the interleukin-1 cytokine family members IL-1F6 and IL-1F8 on adipocyte differentiation. Obesity 18:2234-2236
47. Xoma Ltd (2011) XOMA 052 Phase 2b top line results: glucose control not demonstrated, positive anti-inflammatory effect, cardiovascular biomarker and lipid improvement and safety confirmed. Available from http://investors.xoma. com/releasedetail.cfm?ReleaseID=559470
48. Maedler K, Sergeev P, Ris F et al (2002) Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110:851-860
49. Masters SL, Dunne A, Subramanian SL et al (2010) Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol 11:897-904
50. Lee HM, Kim JJ, Kim HJ, Shong M, Ku BJ, Jo EK (2013) Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes 62:194-204